News

The Phase II study enrolled seven patients with locally advanced rectal cancer. TNFerade was administered weekly to patients via intratumoral injections during the first five weeks of radiotherapy.

The companies entered into the antibody-drug conjugate (ADC) collaboration in April 2005 to provide MedImmune with access to Seattle Genetics’ ADC technology for antibodies targeting up to two

Deerfield’s commitment of funding, which includes $7.5 million upfront, is in the form of an interest-bearing loan that can be drawn down at pre-determined intervals over a three-year

The purchase price is subject to adjustment based on ReliaGene’s working capital at closing and future revenue levels. A portion of the purchase price will be held in

The study will be performed in healthy volunteers who will receive the drug subcutaneously. The evaluations will include safety, tolerability, pharmacokinetics and several pharmacodynamic endpoints, including endogenous messenger

Emisphere added that it will retain its scientific staff and laboratory facilities in Tarrytown. The move to New Jersey is one of several real estate initiatives planned by

The companies have initially targeted four immediate release opioid analgesic products, including Acurox tablets (oxycodone HCl, niacin, and a unique combination of other ingredients), for treating moderate to

The net proceeds to the company of the offering were approximately $24 million, after payment of underwriting discounts and commissions, but excluding estimated offering expenses. Bionovo will use

Under the terms of the agreement, Merck receives worldwide exclusive rights to Heplisav, will fund future vaccine development and be responsible for commercialization. Dynavax will receive an initial